oAlert.pl

Recalled Medicines & supplements – Current GIS Alerts 2026

Found 685 recalled products in the Medicines & supplements category. Check batch numbers, shops, and hazard information.

Common hazards in this category

All recalled products

Hydroxyzinum Hasco – recalled product

Hydroxyzinum Hasco

MEDIUM 05.11.2024

An increase of an unknown contaminant was detected in the 'other single' impurity parameter (hydroxyzine hydrochloride impurity) in batches 010624 and 020624. Potential effects: poisoning, reduced efficacy, adverse reactions.

BIOFLEKS % 0.9 Izotonik Sodyum Klorür çözeltisi Steril – recalled product

BIOFLEKS % 0.9 Izotonik Sodyum Klorür çözeltisi Steril

HIGH 18.10.2024

Observed presence of liquid between the primary container and outer film of unknown origin, indicating possible leakage of a parenteral container. Potential effects: infection, loss of sterility, unpredictable consequences upon administration.

Sugammadex Reig Jofre – recalled product

Sugammadex Reig Jofre

CRITICAL 03.10.2024

The presence of visible silicone particles in the product solution was found; the safety report indicates that potential risk to patients from injection of these particles cannot be excluded. Potential effects: vascular complications, inflammatory reactions, emboli, other injection-related complications.

Sugammadex Reig Jofre – recalled product

Sugammadex Reig Jofre

CRITICAL 03.10.2024

The submitted safety assessment report indicates that potential risk to patients from injection of visible silicone particles cannot be excluded. Potential effects: complications after injection, local or systemic reactions, health risk.

Euvax B – recalled product

Euvax B

CRITICAL 03.10.2024

Due to the occurrence of a threat to public health and a reported adverse post‑vaccination reaction potentially related to administration of this vaccine, the authority identified a real risk to patients’ health and life. Potential effects: serious adverse reactions, post‑vaccination complications, life‑threatening conditions.

Strepsils z miodem i cytryną – recalled product

Strepsils z miodem i cytryną

HIGH 24.09.2024

Contamination of the medicinal product with a substance of unknown origin and nature creates a real risk of unforeseeable medical consequences. Potential effects: poisoning, adverse reactions, lack of treatment efficacy.

Atofab – recalled product

Atofab

HIGH 20.09.2024

Out-of-specification results for atomoxetine content and non-uniform capsule mass, which may reduce product efficacy. Potential effects: reduced or absent therapeutic effect.

Atofab – recalled product

Atofab

HIGH 20.09.2024

Out-of-specification results for atomoxetine content and capsule mass uniformity (OOS) detected in reference tests. Potential effects: reduced efficacy of the medicine.

Atofab – recalled product

Atofab

MEDIUM 20.09.2024

Results out of specification (OOS) for atomoxetine content and non-uniformity of capsule mass in identified batches. Potential effects: reduced therapeutic efficacy.

Atofab – recalled product

Atofab

MEDIUM 20.09.2024

Out-of-specification results for atomoxetine content and non-uniform capsule mass caused by manufacturing defects and changed API particle properties. Potential effects: reduced efficacy of the medicine.

Corhydron 25 – recalled product

Corhydron 25

CRITICAL 18.09.2024

A quality defect was identified consisting of an out-of-specification result for free hydrocortisone content, with this exceedance expected to increase until the end of the shelf-life of batch 110021. Potential effects: reduced efficacy or unpredictable action of this life-saving emergency medicine.

Corhydron 25 – recalled product

Corhydron 25

CRITICAL 18.09.2024

An out-of-specification (OOS) result was found in stability testing for the free hydrocortisone content; further increase is expected until the end of shelf life of batch 110021, which may affect dissolution and the drug’s performance. Potential effects: reduced therapeutic efficacy or unpredictable effects of the injectable medicine.

Symibace – recalled product

Symibace

HIGH 13.09.2024

An exceedance of the specification limit for impurity B was found, which according to the authority represents a real and probable risk to human health. Potential effects: poisoning, complications, lack of treatment safety.

Symibace – recalled product

Symibace

HIGH 13.09.2024

It was found that the specification limit for contamination (Impurity B) in batch 49N013A was exceeded, which means failure to meet established quality requirements and represents a real and probable risk to patients’ health. Potential effects: adverse reactions, treatment complications, possible deterioration of health.

Faringan – recalled product

Faringan

MEDIUM 13.09.2024

Non-compliance with quality requirements was found: too low benzocaine content, exceeding acceptable limits of related substances (including a single unknown impurity), and excessive tablet crumbling in the friability test. Potential effects: reduced treatment efficacy, possible undefined toxicological risk, difficulties in taking crumbled tablets.

Faringan – recalled product

Faringan

MEDIUM 13.09.2024

non-compliance was found consisting in exceeding the lower limit of benzocaine content, exceeding the permissible limit of benzocaine-related substances (single unknown impurity and total impurities), and crumbling of tablets after abrasion resistance testing. Potential effects: lack of treatment efficacy, unknown risk from impurities, possible adverse effects.

Eptifab – recalled product

Eptifab

CRITICAL 29.08.2024

Incorrect information in the leaflet was found: swapped dosing instructions for patients with normal and impaired renal function, which may lead to improper dosing of the injection solution and direct, serious health consequences. Potential effects: poisoning, severe bleeding complications, lack of treatment efficacy, life‑threatening events.

Vabysmo – recalled product

Vabysmo

CRITICAL 29.08.2024

Cracked blisters with needles with transfer filter were found, so the sterility of the needles and the solution for injection is not ensured; a class I defect, potentially life‑threatening for patients. Potential effects: infection, severe ophthalmic complications, life‑threatening conditions.

Vabysmo – recalled product

Vabysmo

CRITICAL 29.08.2024

Cracked blisters with needles with a transfer filter were identified in product packs, so sterility of the needles and the solution for injection is not ensured; the defect was classified as Class I, potentially life‑threatening or posing a serious health risk. Potential effects: severe intraocular infections, ophthalmic complications, sepsis, life‑threatening condition.

Gripblocker Express – recalled product

Gripblocker Express

MEDIUM 29.08.2024

The quality defect consists of cracking of the soft gelatin capsule seams and leakage of the filling into the blister pocket, creating a real risk to patients’ health due to the possibility of receiving an incomplete dose and lack of treatment effectiveness. Potential effects: lack of treatment efficacy, possible complications of the underlying disease.

What to do if you bought a recalled product?

If you have purchased any of the products listed above, stop using or consuming them immediately. You can return the product to the store where you bought it for a full refund. Keep the receipt if possible, but most stores will accept returns even without one.